CARY —  Cary-based Phoenix Cardiac Inc. has raised $2.1 million from six investors, according to a filing with the Securities and Exchange Commission.

Phoenix Cardiac

Phoenix Cardiac

The company filed the Form D and did not disclose what it intends to do with the proceeds.

Phoenix Cardiac develops and designs patented technologies in the cardiac medical device field.

[“Each technology will fulfill a current unmet need in cardiovascular medical procedures by improving upon an existing technology, or by designing a device to serve a need that is clearly defined and acknowledged by medical professionals,” the firm’s website says,]

The company’s president and CEO, Gopal Muppirala, has nearly three decades of experience in the pharmaceutical and healthcare industry.

Before founding the company, Gopal worked for Glaxo, GlaxoWellcome and GlaxoSmithKline for over 20 years and also worked for Bayer. Although his experience began in sales, he has covered a variety of roles including market research, new product development and management.

Gopal has transitioned the company to a full development program with meeting key regulatory milestones and maximizing resources.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.

The filing, made on Aug. 31, can be found online.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism